Vomiting and diarrhea cause a loss of fluids, further contributing to the risk of dehydration
A landmark 2023 New England Journal of Medicine trial found that semaglutide significantly reduced the risk of major adverse cardiovascular events among adults with overweight or obesity, even in the absence of diabetes (NEJM, 2023)
Hence, EGCG protects mitochondrial respiratory enzymes and decreases mitochondrial ROS production in cisplatin-induced nephrotoxicity (Sahin et al., 2010
However, we found that four genes, IL-1, IL8, HSPA1A and FOSL1, were significantly induced by CuCl 2 and Cu(OAc) 2 without inhibiting the cell viability
Compounded semaglutide is not FDA-approved and can vary in quality and effectiveness